Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NASDAQ:CLYM NASDAQ:CRMD NASDAQ:HRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$14.98-11.6%$20.91$89.95▼$99.05$434.20M0.9553,591 shs1.47 million shsCLYMClimb Bio$11.14+3.4%$9.70$1.16▼$12.48$616.72M0.09877,847 shs3.68 million shsCRMDCorMedix$8.65+1.3%$7.69$6.13▼$17.43$669.98M1.461.44 million shs1.41 million shsHRTXHeron Therapeutics$0.40-10.7%$0.89$0.40▼$2.30$85.86M1.583.58 million shs4.39 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics-11.57%-19.42%-41.96%+3.45%+108.34%CLYMClimb Bio+3.44%-0.54%-2.02%+51.98%+731.34%CRMDCorMedix+1.29%+5.88%+9.22%+29.30%-39.72%HRTXHeron Therapeutics-10.74%-10.02%-66.54%-58.26%-80.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$14.98-11.6%$20.91$89.95▼$99.05$434.20M0.9553,591 shs1.47 million shsCLYMClimb Bio$11.14+3.4%$9.70$1.16▼$12.48$616.72M0.09877,847 shs3.68 million shsCRMDCorMedix$8.65+1.3%$7.69$6.13▼$17.43$669.98M1.461.44 million shs1.41 million shsHRTXHeron Therapeutics$0.40-10.7%$0.89$0.40▼$2.30$85.86M1.583.58 million shs4.39 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics-11.57%-19.42%-41.96%+3.45%+108.34%CLYMClimb Bio+3.44%-0.54%-2.02%+51.98%+731.34%CRMDCorMedix+1.29%+5.88%+9.22%+29.30%-39.72%HRTXHeron Therapeutics-10.74%-10.02%-66.54%-58.26%-80.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/ACLYMClimb Bio 3.07Buy$21.6494.22% UpsideCRMDCorMedix 2.75Moderate Buy$15.0073.41% UpsideHRTXHeron Therapeutics 2.00Hold$2.50517.44% UpsideCurrent Analyst Ratings BreakdownLatest HRTX, CLYM, AVTE, and CRMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026CLYMClimb Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026CLYMClimb Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.006/3/2026HRTXHeron Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$2.006/2/2026HRTXHeron Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/15/2026CRMDCorMedix Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/14/2026CRMDCorMedix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/12/2026CLYMClimb Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.005/11/2026HRTXHeron Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/8/2026CLYMClimb Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$15.00 ➝ $17.005/6/2026CLYMClimb Bio Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$21.00(Data available from 6/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ACLYMClimb BioN/AN/AN/AN/A$3.36 per shareN/ACRMDCorMedix$311.71M2.18$2.07 per share4.17$5.14 per share1.68HRTXHeron Therapeutics$154.90M0.49N/AN/A$0.07 per share5.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%N/ACLYMClimb Bio-$59.85M-$0.78N/AN/AN/AN/A-31.45%-30.39%8/11/2026 (Estimated)CRMDCorMedix$163.05M$2.134.0648.06N/A45.25%45.57%24.76%8/6/2026 (Estimated)HRTXHeron Therapeutics-$20.19M-$0.18N/AN/AN/A-20.53%-7,747.30%-8.94%8/11/2026 (Estimated)Latest HRTX, CLYM, AVTE, and CRMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CRMDCorMedix$0.35$0.43+$0.08$0.43$104.96 million$127.43 million5/11/2026Q1 2026HRTXHeron Therapeutics-$0.03-$0.04-$0.01-$0.04$36.72 million$34.71 million5/7/2026Q1 2026CLYMClimb Bio-$0.26-$0.20+$0.06-$0.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ACLYMClimb BioN/AN/AN/AN/AN/ACRMDCorMedixN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78CLYMClimb BioN/A27.8627.86CRMDCorMedix0.332.972.74HRTXHeron Therapeutics17.512.531.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/ACLYMClimb Bio69.76%CRMDCorMedix34.18%HRTXHeron Therapeutics80.01%Insider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%CLYMClimb Bio2.60%CRMDCorMedix3.50%HRTXHeron Therapeutics5.86%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableCLYMClimb Bio957.26 million55.77 millionN/ACRMDCorMedix3078.45 million75.71 millionOptionableHRTXHeron Therapeutics300189.28 million178.19 millionOptionableHRTX, CLYM, AVTE, and CRMD HeadlinesRecent News About These CompaniesHeron Therapeutics (HRTX) Receives a Buy from H.C. WainwrightJune 9 at 8:27 AM | theglobeandmail.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Heron Therapeutics (HRTX) and Praxis Precision Medicines (PRAX)June 6, 2026 | theglobeandmail.comHeron Therapeutics Appeals Ruling Invalidating CINVANTI PatentsJune 4, 2026 | theglobeandmail.comHeron Therapeutics, Inc.: U.S. District Court Issues Decision Regarding CINVANTI PatentsJune 2, 2026 | finanznachrichten.deU.S. District Court Issues Decision Regarding CINVANTI® PatentsJune 2, 2026 | globenewswire.comWhy Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright?May 19, 2026 | insidermonkey.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: ALX Oncology Holdings (ALXO) and Heron Therapeutics (HRTX)May 14, 2026 | theglobeandmail.comHeron Therapeutics (HRTX) price target decreased by 15.38% to 3.74May 14, 2026 | msn.comHeron (HRTX) Q1 2026 Earnings Call TranscriptMay 12, 2026 | finance.yahoo.comAcute Care Revenue Growth Helps Heron (HRTX) Reaffirm 2026 Guidance Despite Q1 Sales DeclineMay 11, 2026 | finance.yahoo.comHeron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call TranscriptMay 11, 2026 | seekingalpha.comHeron Therapeutics (NASDAQ:HRTX) Releases Earnings Results, Misses Expectations By $0.01 EPSMay 11, 2026 | marketbeat.comHeron Therapeutics Q1 Earnings Call HighlightsMay 11, 2026 | marketbeat.comHeron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to SayMay 11, 2026 | zacks.comHeron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue EstimatesMay 11, 2026 | zacks.comHeron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms GuidanceMay 11, 2026 | globenewswire.comAnalysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out forMay 4, 2026 | zacks.comHeron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026April 27, 2026 | globenewswire.comThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarApril 7, 2026 | zacks.comHeron (HRTX) Q4 2025 Earnings Call TranscriptFebruary 28, 2026 | fool.comHeron Therapeutics, Inc. Q4 2025 Earnings Call SummaryFebruary 27, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHRTX, CLYM, AVTE, and CRMD Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$14.98 -1.96 (-11.57%) As of 06/8/2026Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Climb Bio NASDAQ:CLYM$11.14 +0.37 (+3.44%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$11.40 +0.26 (+2.33%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.CorMedix NASDAQ:CRMD$8.65 +0.11 (+1.29%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$8.61 -0.04 (-0.46%) As of 05:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Heron Therapeutics NASDAQ:HRTX$0.40 -0.05 (-10.74%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$0.41 +0.01 (+1.26%) As of 05:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Corning Is Paving AI's Future With Glass The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? From Crypto to AI: Insiders Are Trading These 3 Stocks The Case for Intel Over Pure-Play Quantum Firms Has Temu-Owner PDD's Story Changed After Double Miss? Campbell's Soup Stock: Deep Value and a 7% Dividend Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
